scholarly journals The Oral Pheneticillin Absorption Test: An Accurate Method to Identify Patients with Inadequate Oral Pheneticillin Absorption

Antibiotics ◽  
2019 ◽  
Vol 8 (3) ◽  
pp. 119
Author(s):  
Dijkmans ◽  
Kweekel ◽  
Dissel ◽  
Esdonk ◽  
Kamerling ◽  
...  

Severe streptococcal infections are commonly treated with intravenous followed by oral penicillin (pheneticillin) therapy. However, switching from iv to oral therapy is complicated by the variability in oral pheneticillin absorption. We employed an Oral Absorption Test (OAT) for pheneticillin to identify patients in whom oral pheneticillin absorption is poor. Out of 84 patients 30 patients (36%) were identified as insufficient absorbers. Treatment failure due to pheneticillin malabsorption can be avoided by performing an OAT, and these patients should be treated by another antibiotic, which is known to be absorbed well.

PEDIATRICS ◽  
1965 ◽  
Vol 36 (6) ◽  
pp. 930-932
Author(s):  
Edward A. Mortimer ◽  
Bernard Boxerbaum

In spite of adequate means of therapy, streptococcal disease and its complications continue to present problems to the physician who cares for children. For accurate diagnosis and control of streptococcal disease inexpensive bacteriologic culture facilities are required and the physician must assure himself of the accuracy of the results. To prevent the sequelae of streptococcal occal pharyngitis, therapy sufficient to eradicate the offending organism is required. Optimum therapy of streptococcal infections is intramuscular benzathine penicillin; oral therapy with penicillin or erythromycin should be followed by a throat culture to ensure that the streptococcus has been erdicated.


1972 ◽  
Vol 69 (3) ◽  
pp. 488-496 ◽  
Author(s):  
J. F. F. Lekkerkerker ◽  
F. van Woudenberg ◽  
H. Doorenbos

ABSTRACT The influence of longterm treatment with 15 mg of prednisolone on calcium absorption was investigated by means of an oral absorption test. Plasma-radioactivity was measured one, two and three hours after the oral dose. Sixteen patients were studied before and while on medication during three weeks, eleven of them being re-investigated after five months of treatment. This dose of steroids produced no effect on calcium absorption; two and three hours after the oral dose the plasma-radioactivity is even higher (P < 0.05) while on prednisolone. In six patients the one hour calcium pool size and turnover rate were also measured after iv 45Ca. The pool size and turnover rate were not changed during the treatment.


2019 ◽  
Author(s):  
Faezeh Bakhshi ◽  
Ommoleila Molavi ◽  
Mohammad Reza Rashidi ◽  
Ali Shayanfar ◽  
Hassan Amini

Abstract Objective : Silibinin is an antioxidant agent and is shown to have anticancer effects in different cancers including lung, breast, colorectal, liver, prostate, and kidney. There are challenges in the clinical use of silibinin. The main limitation is low solubility, poor oral absorption, and extensive hepatic metabolism. We aim to develop a High-Performance Liquid Chromatography (HPLC) sensitive method for quantification of silibinin in aqueous samples to quantify its concentration in new formulations. A reverse-phase high-performance liquid chromatography (RP-HPLC) composed of C18 column as stationary phase and the mixture of methanol (90%) and water (10%) as mobile phase. The developed method was validated based on the established guidelines. Results : The retention time for silibinin was seen in 2.97 minute after injection. The calibration curve was drawn and the established method demonstrated a linear ranged from 10 to 100 µg/ml, with a correlation coefficient of 0.996. The sensitivity of the developed method was 10 µg/ml. The accuracy calculated in the range of 88-105.9% and the precision (as relative standard deviation) was between 2.7-10.9%. These results demonstrate that the developed method can be a fast and accurate method for quantification of silibinin in aqueous samples.


2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Faezeh Bakhshi ◽  
Ommoleila Molavi ◽  
Mohammad Reza Rashidi ◽  
Ali Shayanfar ◽  
Hassan Amini

Abstract Objective Silibinin is an antioxidant agent and is shown to have anticancer effects in different cancers including lung, breast, colorectal, liver, prostate, and kidney. There are challenges in the clinical use of silibinin. The main limitation is low solubility, poor oral absorption, and extensive hepatic metabolism. We aim to develop a High-Performance Liquid Chromatography (HPLC) sensitive method for quantification of silibinin in aqueous samples to quantify its concentration in new formulations. A reverse-phase high-performance liquid chromatography (RP-HPLC) composed of C18 column as stationary phase and the mixture of methanol (90%) and water (10%) as mobile phase. The developed method was validated based on the established guidelines. Results The retention time for silibinin was seen in 2.97 min after injection. The calibration curve was drawn and the established method demonstrated a linear ranged from 10 to 100 µg/ml, with a correlation coefficient of 0.996. The sensitivity of the developed method was 10 µg/ml. The accuracy calculated in the range of 88–105.9% and the precision (as relative standard deviation) was between 2.7 and 10.9%. These results demonstrate that the developed method can be a fast and accurate method for quantification of silibinin in aqueous samples.


2013 ◽  
Vol 168 (6) ◽  
pp. 913-917 ◽  
Author(s):  
J N Walker ◽  
P Shillo ◽  
V Ibbotson ◽  
A Vincent ◽  
N Karavitaki ◽  
...  

ObjectiveFor patients who remain hypothyroid despite the administration of what would seem adequate doses of levothyroxine (l-T4), the underlying cause can be difficult to determine. The possibility of a biological cause should first be explored; however, in the majority of cases, poor adherence to medication is likely to be the main cause of treatment failure. When non-adherence is suspected but not volunteered, options to confirm the suspicion are limited. In this study, we identified patients for whom known drugs and pathological causes of l-T4 malabsorption were excluded, and despite often high doses of l-T4, the patients remained hypothyroid.DesignUsing a weight-determined oral l-T4 bolus administration, absorption was initially assessed in 23 patients. In nearly all patients, this was shown to be maximal at 120 min post-ingestion. This was then followed by the continued administration of a weekly T4 bolus for a 4-week period after which TSH and free T4 (fT4) levels were recorded.ResultsAll patients showed a rise in fT4 at 120 min following the administration of the l-T4 bolus, with a mean increase of 54±3% from baseline. Following the treatment period, using an equivalent weekly l-T4 dose, which was significantly less than that of the daily dose taken by the patients before the test, TSH reduced from baseline in ∼75% of cases.ConclusionUsing this combination of tests allows significant malabsorptive problems to be identified first and then potential non-adherence to be demonstrated. A management plan can then be implemented to increase adherence, aiming to improve treatment outcomes.


2013 ◽  
Vol 24 (4) ◽  
pp. 215-216
Author(s):  
Wilson W Chan ◽  
Divya Virmani ◽  
Dylan R Pillai

Intravenous artesunate therapy is the first-line therapy for severe malaria, and is highly efficacious when used in combination with an oral partner drug such as doxycycline or atovaquone-proguanil. However, treatment failure occurs routinely with artesunate monotherapy due to the very short half-life of this drug. In North America, experience with artesunate is limited. With the pressure to discharge patients early, administration of the essential oral partner drug is often left to the discretion of the patient. Thus, treatment failure may be commonplace if nonadherence is a factor, as was observed in the case described in the present report.


2019 ◽  
Author(s):  
Faezeh Bakhshi ◽  
Ommoleila Molavi ◽  
Mohammad Reza Rashidi ◽  
Ali Shayanfar ◽  
Hassan Amini

Abstract Objective : Silibinin is an antioxidant agent and is shown to have anticancer effects in different cancers including lung, breast, colorectal, liver, prostate, and kidney. There are challenges in the clinical use of Silibinin. The main limitation is low solubility, poor oral absorption, and extensive hepatic metabolism. We developed a High-Performance Liquid Chromatography sensitive method for quantification of Silibinin in in-vitro samples to quantify in different formulations. We applied HPLC set, C18 column as stationary phase and the mixture of methanol (90%) and water (10%) as mobile phase. Utilized solutions were daily prepared through serial dilution of stock solution to make specific concentrations ranged between 10 μg/ml to 100 μg/ml. The developed method was validated by credible guidelines. Results : The calibration curve was drawn according to the height peaks of different concentrations and the established method demonstrated a linear ranged from 10 to 100 µg/ml, with a correlation coefficient of 0.996 for in-vitro samples. The retention time was 2.97 min, and the accuracy and precision (inter-day and intra-day) of the developed method was in the range of 88-105.9%. These results demonstrate that the developed method can be a fast and accurate method for quantification of Silibinin in in-vitro samples.


2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S218-S218
Author(s):  
Ashley L Cubillos ◽  
Elisabeth Chandler ◽  
Ian P Murphy ◽  
Robert Castro

Abstract Background High-bioavailability (HIGH-BIO) oral agents (i.e. trimethoprim-sulfamethoxazole, fluoroquinolones) are increasingly utilized for definitive treatment of uncomplicated gram-negative (UGN) bloodstream infections (BSI). Literature supports use of HIGH-BIO agents as step-down therapy, but few studies have assessed use of low-bioavailability (LOW-BIO) agents (i.e. beta-lactams). Increased recurrence of BSI has been associated with LOW-BIO agents; suboptimal dosing of beta-lactam agents may have impacted outcomes. Trials have not assessed whether high-dose beta-lactams (HD-BL) improve clinical outcomes over low-dose beta-lactams (LD-BL) for UGN BSI. Methods This retrospective cohort study conducted between December 2016 and December 2020 included adults with UGN BSI administered oral step-down therapy for at least 1/3rd the total antibiotic duration. The primary outcome was incidence of treatment failure of HIGH-BIO compared to LOW-BIO agents within 90 days of completing oral therapy. Treatment failure was a composite of all-cause mortality, recurrent BSI, reinfection of the primary site, or transition to IV antibiotics after initiating oral therapy. Secondary outcomes were incidence of treatment failure of HIGH-BIO compared to HD-BL agents, and of HD-BL compared to LD-BL agents. Results Of 225 patients, 67 (29.8%) received a HIGH-BIO and 158 (70.2%) a LOW-BIO agent; of those in the LOW-BIO arm 126 (79.7%) received a HD-BL. The most common source of BSI was urinary (202 [89.8%]); transition to oral therapy occurred after a mean of 5 ± 2.39 days. No difference in treatment failure was observed (8 [11.9%] HIGH-BIO vs. 25 [15.8%] LOW-BIO, P = 0.45). A numerically higher number of patients in the LOW-BIO arm had recurrent BSI (4 [2.5%] LOW-BIO vs. 0 [0%] HIGH-BIO, P = 0.18). No difference in treatment failure was observed between HIGH-BIO and HD-BL agents (8 [11.9%] vs. 20 [15.9%], P = 0.46), or HD-BL and LD-BL agents (20 [15.9%] vs. 5 [15.6%], P = 0.97). Conclusion No difference in treatment failure was observed between groups; further study is needed due to failure to reach statistical power. A numerical trend towards increased recurrence of BSI was observed with LOW-BIO agents. Beta-lactams may be reasonable for step-down therapy of UGN BSI if HIGH-BIO agents are contraindicated. Disclosures All Authors: No reported disclosures


Sign in / Sign up

Export Citation Format

Share Document